[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
May 1996

Interleukins 2 and 12 Activate Natural Killer Cytolytic Responses of Peripheral Blood Mononuclear Cells From Patients With Head and Neck Squamous Cell Carcinoma

Arch Otolaryngol Head Neck Surg. 1996;122(5):541-547. doi:10.1001/archotol.1996.01890170073014

Objectives:  To examine the capacity of interleukin-2 (IL-2) and interleukin-12 (IL-12) to modulate the cytolytic activity of peripheral blood mononuclear cells against squamous cell carcinoma, and to determine whether peripheral blood mononuclear cells from healthy donors respond differently to IL-12 than do peripheral blood mononuclear cells from patients with head and neck squamous cell carcinoma.

Design:  Case-comparison study of a consecutive sample of patients with head and neck squamous cell carcinoma who were scheduled to undergo surgical excision.

Participants:  The study included 10 patients with stage III or IV carcinoma matched with 10 volunteer blood donors.

Intervention:  Isolated peripheral blood mononuclear cells from patients and volunteers were treated with IL-2, 10 U/mL and 100 U/mL; IL-12,1 U/mL or 10 U/mL; or a combination of IL-2 and IL-12.

Results:  The combination of IL-2 and IL-12 consistently produced the greatest activation of cytolysis than either cytokine alone at all concentrations tested. This increased activity against a squamous cell carcinoma cell line was seen in lymphocytes from volunteers and patients.

Conclusion:  Our findings suggest a new treatment regimen for the patient with head and neck cancer that uses immunomodulation with a combination of cytokines.(Arch Otolaryngol Head Neck Surg. 1996;122:541-547)